Cyclin E1 protein overexpression sensitizes ovarian cancer cells to ZN-c3, a novel, selective and oral bioavailable inhibitor of Wee1

被引：4
|
作者：
Ma, Jianhui
Liu, Wen
Chung, Heekyung
Izadi, Hooman
DeJong, Petrus
Harismendy, Olivier
Li, Jia
Donate, Fernando
Samatar, Ahmed
Lackner, Mark
Escoubet, Laure
Bunker, Kevin
Kim, Daehwan
Jameson, Nathan
Ozmen, Tugba Yildiran
Jeong, Kangjin
Zhang, Dong
Pan, Wen-An
Mills, Gordon
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2153
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2153
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Cyclin E1 overexpression sensitizes ovarian cancer cells to WEE1 and PLK1 inhibition
    Xi, Qian
    Kunita, Akiko
    Ogawa, Miho
    Ka, Mirei
    Tanimoto, Saki
    Tsuchimochi, Saki
    Nagai, Saeko
    Matsunaga, Asami
    Fukuda, Tomohiko
    Watanabe, Kousuke
    Sone, Kenbun
    Shinozaki-Ushiku, Aya
    Kawana, Kei
    Ushiku, Tetsuo
    Osuga, Yutaka
    Katayama, Kazuhiro
    Kage, Hidenori
    Oda, Katsutoshi
    ONCOGENE, 2025,
  • [2] Cyclin E1 Overexpression as a Predictive Biomarker to WEE1 Inhibition in Ovarian Cancer Cells
    Xi, Qian
    Kage, Hidenori
    Ogawa, Miho
    Kunita, Akiko
    Ka, Mirei
    Matsunaga, Asami
    Watanabe, Kousuke
    Sone, Kenbun
    Kawana, Kei
    Osuga, Yutaka
    Oda, Katsutoshi
    CANCER SCIENCE, 2025, 116 : 1811 - 1811
  • [3] Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer
    Huang, Peter Q.
    Boren, Brant C.
    Hegde, Sayee G.
    Liu, Hui
    Unni, Aditya K.
    Abraham, Sunny
    Hopkins, Chad D.
    Paliwal, Sunil
    Samatar, Ahmed A.
    Li, Jiali
    Bunker, Kevin D.
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (17) : 13004 - 13024
  • [4] Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition
    Chen, Xian
    Low, Kwang-Huei
    Alexander, Angela
    Jiang, Yufeng
    Karakas, Cansu
    Hess, Kenneth R.
    Carey, Jason P. W.
    Bui, Tuyen N.
    Vijayaraghavan, Smruthi
    Evans, Kurt W.
    Yi, Min
    Ellis, D. Christian
    Cheung, Kwok-Leung
    Ellis, Ian O.
    Fu, Siqing
    Meric-Bernstam, Funda
    Hunt, Kelly K.
    Keyomarsi, Khandan
    CLINICAL CANCER RESEARCH, 2018, 24 (24) : 6594 - 6610
  • [5] Pharmacodynamic evidence for WEE1 target engagement in surrogate and tumor tissues from a phase I study of the WEE1 inhibitor ZN-c3
    Chalasani, P.
    Tolcher, A.
    Meric-Bernstam, F.
    Mamdani, H.
    de Jong, P. R.
    Anderes, K.
    Samatar, A. A.
    Sergeeva, M.
    Gazdoiu, M.
    Viana, M. R.
    Pultar, P.
    Voliotis, D.
    Donate, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S593 - S593
  • [6] PHASE 1B DOSE-ESCALATION STUDY OF ZN-C3 (WEE1 INHIBITOR) WITH CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN, PERITONEAL, OR FALLOPIAN TUBE CANCER: ZN-C3 PLUS GEMCITABINE ARM
    Thaker, Premal
    Pasic, Anes
    Richardson, Gary
    Vranjes, Zivko
    Prather, Stanislava
    Makris, Lukas
    Misir, Soamnauth
    Pultar, Philippe
    Voliotis, Dimitris
    Fu, Siqing
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A242 - A242
  • [7] Overexpression of PAXIP1 potentiates WEE1 inhibitor action in lung cancer cells
    Jhuraney, Ankita
    Woods, Nicholas T.
    Kinose, Fumi
    Cress, Douglas W.
    Gray, Jhanelle E.
    Haura, Eric B.
    Rix, Uwe
    Monteiro, Alvaro N.
    CANCER RESEARCH, 2014, 74 (19)
  • [8] Tumor pharmacokinetics, pharmacodynamics and efficacy analysis of WEE1 inhibitor, zn-c3 in patient- derived xenograft models of glioblastoma
    Mehta, Shwetal
    Tien, An-Chi
    Patel, Sonam
    Margaryan, Tigran
    Shivanna, Anilkumar Thaghalli
    Elena, Leonel
    Molloy, Jennifer
    Knight, William
    Hon, Ruiheng
    Elliott, Mackenna
    Stavnichuk, Mariya
    Opachich, Zorana
    Chang, Yu-Wei
    Montgomery, Chelsea
    Himes, Sarah
    Hopkins, Barbara
    Tovmasyan, Artak
    Sanai, Nader
    CANCER RESEARCH, 2023, 83 (07)
  • [9] Correlation of cyclin E1 expression and clinical outcomes in a phase 1b dose-escalation study of azenosertib (ZN-c3), a WEE1 inhibitor, in combination with chemotherapy (CT) in patients (pts) with platinum-resistant or refractory (R/R) epithelial ovarian, peritoneal, or fallopian tube cancer (EOC)
    Liu, Joyce F.
    Fu, Siqing
    Richardson, Gary Edward
    Vranjes, Zivko
    Meniawy, Tarek
    Shannon, Catherine M.
    Hamilton, Erika P.
    Blank, Stephanie V.
    Mathews, Cara Amanda
    Alidzanovic, Jasmina
    Ruseva, Rossitza Krasteva
    Shi, Qing
    Harismendy, Olivier
    Ptaszynski, Ann M.
    Westin, Shannon Neville
    Meric-Bernstam, Funda
    Thaker, Premal H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] A phase Ib dose-escalation study of ZN-c3, a WEE1 inhibitor, in combination with chemotherapy in patients with platinum-resistant or -refractory ovarian, peritoneal, or fallopian tube cancer
    Fu, S.
    Pasic, A.
    Richardson, G.
    Vranjes, Z. J.
    Meniawy, T.
    de Jong, P. R.
    Donate, F.
    Samatar, A. A.
    Rodriguez, J.
    Pultar, P.
    Voliotis, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S618 - S618
12345